Recent articles
Here's Why Translate Bio Dropped Today
The company announced a stock offering to raise cash, but today's drop could've been much worse.
Here's Why PTC Therapeutics Fell as Much as 12.5% Today
The business is raising cash through two offerings: one of debt and one of common stock.
Here's Why Bloom Energy Is Tumbling Today
Investors continue to sour on the solid oxide fuel cell developer.
Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.
The potential is significant. Unfortunately, so is the hype.
This Small-Cap Pharma Expects 3 Late-Stage Data Readouts Soon
Throw in initial results from an important phase 2 clinical trial and investors might see four major pipeline events before the end of 2019.
This Company Is Looking to Win Big in Gene Therapy
It's not a household name, but has made a splash in tackling the biggest pain point in gene therapy: manufacturing.
2 Top Renewable Energy Stocks in Solar Power
These companies don't manufacture solar panels, but they do help customers generate electricity from the sun much more efficiently.
Here's Why Mallinckrodt Fell as Much as 14% Today
Investors continue to grapple with the uncertainty hanging over the company.
Here's Why Lexicon Pharmaceuticals Is Soaring This Week
The company will receive a big windfall for a terminated collaboration. What happens next?
Here's Why Apellis Pharmaceuticals Is Tumbling Today
The company is issuing convertible debt to pad its balance sheet and fund late-stage clinical trials.
Is Lannett Company a Turnaround Stock Worth Buying?
The generic drug distributor ended its fiscal year riding a surge of momentum -- and shares have doubled in the last month.
This Renewable Energy Stock Has a Clear Growth Runway to 2030
The United States could soon be adding 35,000 megawatts of new wind and solar capacity per year. Can this business capitalize on this opportunity?
Here's Why Repligen Has Dropped as Much as 13.1% Today
The bioprocessing leader is having a bad day, but there doesn't appear to be any reason to panic.
Here's Why bluebird bio Fell 21.3% in August
Wall Street has soured on the company's prospects as it eyes a transition to commercial operations.
Here's Why Sarepta Therapeutics Dropped 39.4% in August
Regulators raised concerns with two of the company's drug candidates.
Here's Why Sociedad Quimica y Minera de Chile SA Fell 16.4% in August
The lithium producer reported second-quarter 2019 operating results that showed the impact of significant headwinds.
Here's Why Elanco Animal Health Fell 21.1% in August
The company's reliance on livestock animal products continues to weigh on operating results, so it announced a huge transaction to address that weakness.
Here's Why Teva Pharmaceuticals Dropped 13% in August
Investors continued to back away from the troubled generic-drug company as lawsuits from the opioid crisis began to conclude.
Here's Why Zoetis Gained 10% in August
The animal health leader reported solid second-quarter 2019 operating results, but headwinds are brewing.
Here's Why Tyson Foods Gained 17% in August
The food company reported solid quarterly earnings last month, but shares have given up half their gains since the start of September.